**Core tip:** Previous studies reported that the results of hepatectomy for non-colorectal, non-neuroendocrine liver metastasis (NCNNLM) showed an acceptable prognosis in the heterogeneous disease group. However, considering the indication of hepatectomy for NCNNLM, it is important to define the features of each primary disease. The present review paper describes the general prognosis and risk factors associated with NCNNLM, specifically focuses on liver metastasis associated with each primary disease. A multidisciplinary approach that takes appropriate timing for hepatectomy combined with chemotherapy into consideration may prolong survival and/or contribute to the improvement of the quality of life, while taking time off from systemic chemotherapy.

INTRODUCTION
============

Metastatic disease from solid organ tumors occurs frequently in the liver. Presently, surgical resection has been widely accepted as a treatment for colorectal cancer liver metastases\[[@B1],[@B2]\] and liver metastases of neuro-endocrine tumors\[[@B3],[@B4]\], providing a relatively better prognosis, whereas, the indications and prognosis of hepatectomy for non-colorectal non-neuroendocrine liver metastases (NCNNLM) remain controversial owing to the rarity of the disease. The biological behavior of NCNNLM varies depending on its primary origin. Discussion of this heterogeneous disease group should be performed in the order from its general to specific aspects. To date, no prospective randomized study has been conducted in this limited field; therefore, in this report we provide a general review of large cohort retrospective studies on hepatectomy for NCNNLM and a more specific review on hepatectomy for liver metastases from different primaries.

LITERATURE AND RESEARCH
=======================

In this report, we reviewed the literature reporting NCNNLM in a large number of patients and their specific primaries. More precisely, we reviewed articles in the English literature that included ≥ 100 cases with NCNNLM and relatively large case series for the specific primary (for liver metastases from gastric cancer, breast cancer, and melanoma, reports that included ≥ 40 cases were reviewed because of the limited availability of cases in many studies). Using the results reported in the selected literature, the survival outcomes and statistically significant risk factors that impacted survival by multivariate analysis (univariate analysis for some report) were evaluated.

Prognosis and risk factors after hepatectomy for NCNNLM
-------------------------------------------------------

Along with increased evidence of prolonged survival by hepatectomy in patients with colorectal and neuroendocrine liver metastases, Schwartz et al\[[@B5]\] initially categorized NCNNLM and reviewed the literatures in 1995, followed by the analysis of prognosis in a large cohort study by Harrison et al\[[@B6]\] in 1997. Many validation studies were performed in other patient cohorts that are summarized in Table [1](#T1){ref-type="table"}\[[@B7]-[@B16]\]. In the present report, we reviewed the 10 largest studies, each with ≥ 100 patients who underwent hepatectomy for NCNNLM. In this cohort, the 3- and 5-year overall survival rates were reported as 34%-57% and 19%-42%, respectively, with median survival times of 23-49 mo. The 3- and 5-year disease-free survival rates were 21%-37% and 18%-29%, respectively, with median disease-free survival times of 10-21 mo. The postoperative mortality and morbidity rates were reported 0%-5% and 18%-33%, respectively. In these cohort studies, the reported negative risk factors for survival were the margin status in six studies\[[@B8]-[@B11],[@B15],[@B16]\]; primary tumor type in four\[[@B8],[@B10],[@B11],[@B15]\]; shorter disease-free interval between primary tumor resection and hepatectomy\[[@B8],[@B10],[@B15]\] and extrahepatic disease\[[@B10],[@B12],[@B16]\] in three; postoperative complications\[[@B14],[@B16]\], larger hepatic metastasis in diameter\[[@B12],[@B13]\], and squamous cell histology\[[@B10],[@B15]\] in two; and age\[[@B10]\], major hepatectomy\[[@B10]\], minor hepatectomy\[[@B15]\], synchronous metastasis\[[@B11]\], lymphovascular invasion\[[@B13]\], stromal tumor histology\[[@B15]\] and \> 3 liver metastases\[[@B16]\] in one (Table [1](#T1){ref-type="table"}). Negative risk factors for recurrence were extrahepatic disease\[[@B12],[@B16]\] in two studies; and primary tumor\[[@B8]\], disease-free interval\[[@B8]\], larger hepatic metastasis in diameter\[[@B12]\], blood transfusion\[[@B14]\], preoperative chemotherapy\[[@B14]\], \> 3 liver metastases\[[@B16]\], and residual tumor\[[@B16]\] in one. Patients with liver metastases from breast cancer showed significantly better survival in three studies\[[@B10],[@B11],[@B15]\], whereas those with liver metastases from genitourinary tumor liver showed better survival in one\[[@B11]\], and patients with liver metastases from melanoma showed poorer survival compared to other primaries in two studies\[[@B10],[@B15]\] (Table [2](#T2){ref-type="table"}).

###### 

Summary of studies each of which included ≥ 100 patients who underwent hepatectomy for non-colorectal non-neuroendocrine liver metastases (overall survival)

  **Ref**.                     **Year**   **Period**   **No. of patients**                   **Primary tumor (GI/breast/GU/melanoma/sarcoma/others)**   **MST (mo)**                         **3-ysr (%)**   **5-ysr (%)**                        **Factors associated with worse overall survival**
  ---------------------------- ---------- ------------ ------------------------------------- ---------------------------------------------------------- ------------------------------------ --------------- ------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------
  Elias et al\[[@B7]\]         1998       1984-1996    120[1](#T1FN1){ref-type="table-fn"}   (22/35/31/10/13/9)                                         NR                                   NR              36[2](#T1FN2){ref-type="table-fn"}   NR
  Yedibela et al\[[@B9]\]      2005       1978-2001    150[1](#T1FN1){ref-type="table-fn"}   (50/24/11/5/15/45)                                         23[2](#T1FN2){ref-type="table-fn"}   NR              26[2](#T1FN2){ref-type="table-fn"}   Margin status (R1,2)
  Weitz et al\[[@B8]\]         2005       1981-2002    141                                   (12/29/50/17/0/33)                                         42                                   57              NR                                   Primary tumor type, disease-free interval ≤ 24 mo, margin status (R1,2)
  Adam et al\[[@B10]\]         2006       1983-2004    1452                                  (314/460/332/148/0/198)                                    35                                   49              36                                   Age, primary tumor (ocular melanoma, non-breast), squamous tumor, disease-free interval, extrahepatic disease, major hepatectomy, margin status (R1,2)
  Lendoire et al\[[@B11]\]     2007       1989-2006    106                                   (7/19/40/6/23/11)                                          27                                   34              19                                   Primary tumor (non-breast, non-GU), synchronous metastasis, margin status (R1,2)
  O\'Rourke et al\[[@B12]\]    2008       1986-2006    102                                   (27/11/31/20/3/10)                                         42                                   56              39                                   Diameter of liver metastasis \> 5 cm, extrahepatic nodal disease
  Groeschl et al\[[@B13]\]     2012       1990-2009    420                                   (13/15/92/31/98/71)                                        49                                   50              31                                   Diameter of liver metastasis ≥ 5 cm, lymphovascular invasion
  Takemura et al\[[@B14]\]     2013       1993-2009    145                                   (91/30/12/1/8/3)                                           42                                   55              41                                   Postoperative complication
  Hoffmann et al\[[@B15]\]     2015       2001-2012    150                                   (30/42/33/15/9/21)                                         46                                   NR              42                                   Primary tumor (melanoma, non-breast), interval \< 24 mo, squamous tumor, non-stromal tumor, minor hepatectomy, margin (R2)
  Schiergens et al\[[@B16]\]   2016       2003-2013    167                                   (43/16/61/8/25/14)                                         35                                   49              NR                                   \> 3 liver metastases, extrahepatic disease, residual tumor (R1,2), major complications

Patients with neuroendocrine tumors were excluded;

Results including neuroendocrine tumors. GI: Gastrointesti; GU: Genitourinary; MST: Median survival time; ysr: Year survival rate; NR: Not reported.

###### 

Summary of studies each of which included ≥ 100 patients who underwent hepatectomy for non-colorectal non-neuroendocrine liver metastases (disease-free survival)

  **Ref**.                     **Year**   **No. of patients**                   **MDFST (mo)**   **3-ydfsr (%)**   **5-ydfsr (%)**                      **Factors associated with worse disease-free survival**
  ---------------------------- ---------- ------------------------------------- ---------------- ----------------- ------------------------------------ --------------------------------------------------------------------
  Elias et al\[[@B7]\]         1998       120[1](#T2FN1){ref-type="table-fn"}   NR               NR                28[2](#T2FN2){ref-type="table-fn"}   NR
  Yedibela et al\[[@B9]\]      2005       150[1](#T2FN1){ref-type="table-fn"}   NR               NR                NR                                   NR
  Weitz et al\[[@B8]\]         2005       141                                   17               30                NR                                   Primary tumor, diseas-free interval ≤ 24 mo
  Adam et al\[[@B10]\]         2006       1452                                  13               27                21                                   NR
  Lendoire et al\[[@B11]\]     2007       106                                   NR               NR                NR                                   NR
  O\'Rourke et al\[[@B12]\]    2008       102                                   18               37                27                                   Diameter of liver metastasis \> 5 cm, extrahepatic nodal disease
  Groeschl et al\[[@B13]\]     2012       420                                   NR               NR                NR                                   NR
  Takemura et al\[[@B14]\]     2013       145                                   10               21                18                                   Blood transfusuion, preoperative chemotherapy
  Hoffmann et al\[[@B15]\]     2015       150                                   21               36                29                                   NR
  Schiergens et al\[[@B16]\]   2016       167                                   15               NR                NR                                   \> 3 liver metastases, extrahepatic disease, residual tumor (R1,2)

Patients with neuroendocrine tumors were excluded;

Results including neuroendocrine tumors. MDFST: Median disease-free survival time; ydfsr: Year disease-free survival ratio; NR: Not reported.

As previously mentioned, the type of primary origin was one of the greatest predictors of survival in patients with this heterogeneous disease. Among the 10 largest studies, the most dominant primary origin was the breast\[[@B7],[@B10],[@B13],[@B15]\] and genitourinary\[[@B8],[@B11],[@B12],[@B16]\] in four studies and gastrointestinal tract in two\[[@B9],[@B14]\]. Elias et al\[[@B7]\] and Yedibela et al\[[@B9]\] commented that the resection of liver metastases from gastrointestinal adenocarcinoma correlated with a poor prognosis; however, a more recent report by Takemura et al\[[@B14]\] showed acceptable prognosis after resection of liver metastases from gastrointestinal carcinoma in their largest cohort with a median survival time of 33.5 mo after hepatectomy. As Yedibela et al\[[@B9]\] and Groeschl et al\[[@B13]\] reported that in the more recent years, patients undergoing hepatectomy for NCNNLM appeared to have longer survival compared to previous years, advances in chemotherapy regimens might contribute to prolong survival after the resection of NCNNLM. Adam et al\[[@B10]\] developed a risk model based on their results of multivariate prognostic factor analysis, which was validated by Lendoire et al\[[@B11]\]. Their risk model can efficiently stratify the patients into groups; however, the prognosis of each group differed between the two studies depending on the heterogeneous backgrounds of the patient. To facilitate discussion, the prognosis of each primary disease after hepatectomy for NCNNLM has been discussed separately in following section.

LIVER METASTASES FROM GASTROINTESTINAL PRIMARY TUMORS
=====================================================

Gastric cancer liver metastases
-------------------------------

In the present report, we reviewed the largest 8 studies, each with ≥ 40 patients who underwent hepatectomy for liver metastases from gastric cancer. In this series, the 3- and 5-year overall survival rates were reported as 14%-51% and 9%-42%, respectively, with median survival times of 12-41 mo (Table [3](#T3){ref-type="table"})\[[@B10],[@B17]-[@B23]\]. Among these studies, the negative risk factors for survival were multiple liver metastases in three studies\[[@B18],[@B20],[@B23]\]; larger hepatic metastasis in diameter\[[@B19],[@B21]\] and serosal invasion of primary gastric cancer\[[@B19],[@B21]\] in two; and synchronous hepatic metastases\[[@B17]\], \> 3 liver metastases\[[@B21]\] and \> 2 positive regional lymph node metastases of primary gastric cancer\[[@B23]\] in one (Table [3](#T3){ref-type="table"}). The results of hepatectomy for liver metastasis from gastric cancer are influenced by the statuses of both the primary cancer and liver metastasis. The recent meta-analysis of gastric cancer liver metastases revealed that the surgical resection of liver metastases from gastric cancer was associated with a significantly improved survival and among the patients who underwent surgical resection, patients with solitary hepatic metastasis demonstrated a significantly prolonged survival compared to patients with multiple hepatic metastases\[[@B24]\]. Compared to colorectal liver metastasis, reports on aggressive repeat hepatectomy have been highly limited\[[@B25]\], which might be owing to the frequent occurrence of extrahepatic recurrence such as peritoneal seeding and lymph node recurrence. However, advancements in effective chemotherapy regimens can expand not only the prognosis but also the surgical indications for hepatectomy in patients with liver metastasis from gastric cancer and colorectal live metastases alike.

###### 

Summary of studies each of which included ≥ 40 patients who underwent hepatectomy for liver metastasis from gastric cancer

  **Ref**.                                               **Year**   **Period**   **No. of patients**   **MST (mo)**   **3-ysr (%)**   **5-ysr (%)**   **Factors associated with worse overall survival**
  ------------------------------------------------------ ---------- ------------ --------------------- -------------- --------------- --------------- ----------------------------------------------------------------------------------------------------------------
  Ambiru et al\[[@B17]\]                                 2001       1975-1999    40                    12             NR              18              Synchronous metastasis
  Adam et al\[[@B10]\][1](#T3FN1){ref-type="table-fn"}   2006       1983-2004    64                    15             NR              27              NR
  Cheon et al\[[@B18]\]                                  2008       1995-2005    41                    18             32              21              Multiple liver metastases
  Takemura et al\[[@B19]\]                               2012       1993-2011    64                    34             50              37              Serosal invasion of primary gastric cancer, maximum hepatic metastasis diameter \> 5 cm
  Aizawa et al\[[@B20]\]                                 2014       1997-2010    53                    27             NR              18              Multiple liver metastases
  Kinoshita et al\[[@B21]\]                              2014       1990-2010    256                   31             42              31              Serosal invasion of primary gastric cancer, \> 3 liver metastases, maximum hepatic metastasis diameter \> 5 cm
  Tiberio et al\[[@B22]\]                                2015       1997-2011    53                    13             14              9               NR[2](#T3FN2){ref-type="table-fn"}
  Oki et al\[[@B23]\]                                    2015       2000-2010    69                    41             51              42              Multiple liver metastases, \> 2 positive regional lymph node metastases of primary gastric cancer

As a part of the report of on-colorectal non-neuroendocrine liver metastases;

Only risk factors including palliative patients were reported. MST: Median survival time; ysr: Year survival rate; NR: Not reported.

Gastrointestinal stromal tumors liver metastases
------------------------------------------------

The 7 largest studies on the hepatectomy for liver metastases from gastrointestinal stromal tumors (GIST) reported 50%-90% and 30%-76% overall 3- and 5-year survival rates, respectively, with median survival times of 33-96 mo (Table [4](#T4){ref-type="table"})\[[@B26]-[@B32]\]. Non-surgical therapy\[[@B28],[@B31]\], positive resection margin\[[@B30],[@B32]\], and extrahepatic disease\[[@B29],[@B30]\] in two studies each and a disease free interval ≤ 24 mo\[[@B26]\], absence of tyrosine kinase inhibitor (TKI) therapy\[[@B29]\], male patients\[[@B30]\] and progression disease to TKI therapy at the time of surgery\[[@B30]\] were the factors associated with worse survival (Table [4](#T4){ref-type="table"}). Different from other NCNNLMs, the emergence of TKI dramatically changed the treatment and prognoses of patients with advanced GIST. The role of surgical resection in the treatment of metastatic GIST had remained unclear in the initial era of treatment with TKI\[[@B33]\]; however, recent reports showed evidence that surgical resection combined with TKI offered better prognosis than TKI monotherapy\[[@B29],[@B31],[@B32]\]. As Bauer et al\[[@B30]\] reported progression disease to TKI therapy at the time of surgery, an urgent issue to debate is the appropriate duration of preoperative therapy to minimize the risk of acquiring secondary mutations responsible for TKI resistance\[[@B26],[@B29]\].

###### 

Summary of studies with relatively large cohort of patients who underwent hepatectomy for liver metastasis from gastrointestinal stromal tumors

  **Ref**.                   **Year**   **Period**   **No. of patients underwent hepatectomy**   **MST (mo)**                         **3-ysr (%)**                        **5-ysr (%)**                        **3-yPFS (%)**                       **No. of patients with TKI**               **Factors associated with worse overall survival**
  -------------------------- ---------- ------------ ------------------------------------------- ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  DeMatteo et al\[[@B26]\]   2001       1982-2000    34[1](#T4FN1){ref-type="table-fn"}          39[1](#T4FN1){ref-type="table-fn"}   50[1](#T4FN1){ref-type="table-fn"}   30[1](#T4FN1){ref-type="table-fn"}   45[1](#T4FN1){ref-type="table-fn"}   NR                                         Interval from primary tumor diagnosis ≤ 24 mo[2](#T4FN2){ref-type="table-fn"}
  Nunobe et al\[[@B27]\]     2005       1984-2003    18                                          36                                   64                                   34                                   NR                                   3 (17%)                                    NR
  Xia et al\[[@B28]\]        2010       2005         19                                          33 (mean)                            90                                   NR                                   NR                                   19 (100%)                                  Non-surgical therapy[2](#T4FN2){ref-type="table-fn"}
  Turley et al\[[@B29]\]     2012       1995-2010    39                                          Not reached at 5 yr                  68                                   NR                                   NR                                   27 (73%)[3](#T4FN3){ref-type="table-fn"}   Non-TKI therapy, extrahepatic disease
  Bauer et al\[[@B30]\]      2014       Until 2011   104                                         96                                   NR                                   NR                                   NR                                   \> 84%                                     Male[4](#T4FN4){ref-type="table-fn"}, R2 resection[4](#T4FN4){ref-type="table-fn"}, progression disease to TKI at the time of surgery[4](#T4FN4){ref-type="table-fn"}, extrahepatic disease[4](#T4FN4){ref-type="table-fn"}
  Du et al\[[@B31]\]         2014       NR           19                                          Not reached                          NR                                   NR                                   88 (2-yr)                            19 (100%)                                  Non-surgical therapy[2](#T4FN2){ref-type="table-fn"}
  Seesing et al\[[@B32]\]    2016       1999-2014    48                                          90                                   80                                   76                                   67                                   42 (88%)                                   Margin status (R1,2)

Including gastrointestinal sarcoma;

Copmarison to the non-operation group;

Excluding two patients lost to follow-up;

Results including resections of extrahepatic metastasis. GIST: Gastrointestinal stromal tumor; MST: Median survival time; ysr: Year survival rate; PFS: Progression-free survival; TKI: Tyrosine kinase inhibitor; NR: Not reported.

Other gastro-intestinal primary tumor liver metastases
------------------------------------------------------

Pertaining to reports of liver resection for other gastro-intestinal primary liver metastases that rarely indicated hepatectomy, esophagus and pancreas cancer liver metastasis showed dismal prognosis with a median overall survival time of 7-20 mo\[[@B10],[@B16],[@B34],[@B35]\]. In the meanwhile, intestinal type primary tumors such as duodenal, ampullary and small intestinal cancer showed relatively better prognosis with median survival times of 23-58 mo\[[@B10],[@B34]\] (Table [5](#T5){ref-type="table"}).

###### 

Summary of studies with relatively large cohort of patients who underwent hepatectomy for liver metastases from gastrointestinal primaries other than gastric cancer and gastrointestinal stromal tumors

  **Disease**      **Ref**.                                                     **Year**   **Period**   **No. of patients**   **MST (mo)**                                      **3-ysr (%)**   **5-ysr (%)**   **Factors associated with worse overall survival**
  ---------------- ------------------------------------------------------------ ---------- ------------ --------------------- ------------------------------------------------- --------------- --------------- ----------------------------------------------------
  Peri-ampullary   De Jong et al\[[@B34]\]                                      2010       1993-2009    40                    17 \[23 (intestinal), 13 (pancreaticobiliary)\]   18              NR              Intestinal type (ampullary or duodenal) tumors
  Ampullary        Adam et al\[[@B10]\][1](#T5FN1){ref-type="table-fn"}         2006       1983-2004    15                    38                                                NR              46              NR
  Small bowel      Adam et al\[[@B10]\][1](#T5FN1){ref-type="table-fn"}         2006       1983-2004    28                    58                                                NR              49              NR
  Pancreas         Adam et al\[[@B10]\][1](#T5FN1){ref-type="table-fn"}         2006       1983-2004    40                    20                                                NR              25              NR
                   Schiergens et al\[[@B16]\][1](#T5FN1){ref-type="table-fn"}   2016       2003-2013    19                    7                                                 17              NR              NR
  Esophagous       Adam et al\[[@B10]\][1](#T5FN1){ref-type="table-fn"}         2006       1983-2004    20                    16                                                32              NR              NR
                   Ichida et al\[[@B35]\]                                       2013       2003-2005    5                     13                                                NR              NR              NR

As a part of the report of on-colorectal non-neuroendocrine liver metastases. MST: Median survival time; ysr: Year survival rate; NR: Not reported.

LIVER METASTASES FROM BREAST CANCER
===================================

The largest 10 studies, each with ≥ 40 patients who underwent hepatectomy for liver metastases from breast cancer were reviewed. In this series, the 3- and 5-year overall survivals rates were 49%-68% and 27%-53%, respectively, with median survival times of 41-115 mo (Table [6](#T6){ref-type="table"})\[[@B10],[@B13],[@B15],[@B36]-[@B42]\]. The negative prognostic predictive factors were short disease-free interval\[[@B36],[@B39]\], negative expression of hormone receptors\[[@B37],[@B40]\], poor response to systemic chemotherapy before surgery\[[@B38],[@B40]\], and positive hepatic resection margin\[[@B38],[@B39]\] in two studies; and the absence of repeat hepatectomy\[[@B38]\], non-hepatectomy\[[@B41]\], bone metastasis\[[@B41]\], lymph node metastasis in the primary tumor\[[@B42]\], absence of trastuzumab therapy\[[@B42]\], and multiple liver metastases\[[@B42]\] in one (Table [6](#T6){ref-type="table"}). Some prognostic factors of liver metastases from breast cancer are unique and different from other NCNNLMs, which could indicate that the presence of hormone receptors and HER2 overexpression requires the use of chemotherapy and/or hormone therapy and influences patient survival. Neuman et al\[[@B43]\] suggested that the impact of local control for liver metastases from breast cancer was greatest in the presence of effective targeted therapy. Similar to other NCNNLMs, surgical resection before progression of disease even with chemotherapy might result in better outcomes of selected patients with liver metastases from breast cancer\[[@B40]\]. As Sadot et al\[[@B42]\] advocated in their study, hepatic resection for liver metastases from breast cancer might not confer a survival advantages; however, might allow time off from systemic chemotherapy.

###### 

Summary of studies with ≥ 40 patients who underwent hepatectomy for liver metastasis from breast cancer

  **Ref**.                                                   **Year**   **Period**   **No. of patients**                  **MST (mo)**                         **3-ysr (%)**   **5-ysr (%)**                        **MDFS (mo)**   **Factors associated with worse overall survival**
  ---------------------------------------------------------- ---------- ------------ ------------------------------------ ------------------------------------ --------------- ------------------------------------ --------------- -------------------------------------------------------------------------------------------------------
  Pocard et al\[[@B36]\]                                     2000       1988-1997    52                                   42                                   49              NR                                   NR              Disesase free interval ≤ 48 mo (univariate)
  Elias et al\[[@B37]\]                                      2003       1986-2000    54                                   34                                   50              34                                   NR              Hormone receptor-negative
  Adam et al\[[@B38]\]                                       2006       1984-2004    85                                   32                                   NR              37                                   20              Poor response to preoperative chemotherapy, R2, no repeat hepatectomy
  Adam et al\[[@B10]\][1](#T6FN1){ref-type="table-fn"}       2006       1983-2004    454                                  45                                   NR              41                                   NR              NR
  Hoffman et al\[[@B39]\]                                    2010       1999-2008    41                                   58                                   68              48                                   34              Positive resection margin, disease-free interval \< 24 mo
  Abbott et al\[[@B40]\]                                     2012       1997-2010    86                                   57                                   NR              44                                   14              ER-negative, disease progression before hepatectomy
  Groeschl et al\[[@B13]\][1](#T6FN1){ref-type="table-fn"}   2012       1990-2009    115                                  52                                   52              27                                   22              NR
  Mariani et al\[[@B41]\]                                    2013       1988-2007    51                                   91                                   NR              NR                                   NR              Non-hepatectomy[3](#T6FN3){ref-type="table-fn"}, bone metastasis[4](#T6FN4){ref-type="table-fn"}
  Hoffmann et al\[[@B15]\][1](#T6FN1){ref-type="table-fn"}   2015       2001-2012    42                                   63                                   NR              53                                   NR              NR
  Sadot et al\[[@B42]\]                                      2016       1991-2014    69[2](#T6FN2){ref-type="table-fn"}   50[2](#T6FN2){ref-type="table-fn"}   NR              38[2](#T6FN2){ref-type="table-fn"}   29              Lymph node metastasis in the primary tumor, absence of trastuzumab therapy, multiple liver metastases

As a part of the report of on-colorectal non-neuroendocrine liver metastases;

Including 18 patients who underwent percutaneous ablation therapy;

Comparison to the non-operation group;

Comparison including patients without hepatectomy. MST: Median survival time; ysr: Year survival rate; NR: Not reported.

LIVER METASTASES FROM MELANOMA
==============================

The largest four studies, each with ≥ 40 patients who underwent liver resection for liver metastases from melanoma, reported an overall 5-year survival rate of approximately 7%-20% with a median survival time of 14-28 mo (Table [7](#T7){ref-type="table"})\[[@B10],[@B44]-[@B46]\]. Short disease-free interval from the diagnosis of primary tumor\[[@B45]\], positive resection margin\[[@B45]\], \> 4 liver metastases\[[@B45]\], miliary disease of the primary melanoma\[[@B45]\], cutaneous melanoma\[[@B46]\], and no preoperative chemotherapy were the risk factors predicting poor patients survival (Table [7](#T7){ref-type="table"}). The metastatic pathway of ocular and cutaneous melanomas is different. Ocular melanoma often spreads hematogenously to the liver because there are no lymphatics in the uveal tract. In contrast, cutaneous melanomas potentially spread to the lung, lymph node and soft tissue, and infrequently to the liver\[[@B47]\]. Liver metastases from ocular melanoma often recur within the liver, whereas cutaneous melanoma is more likely to develop extrahepatic recurrence\[[@B44]\]. Surgical resection should be performed concomitantly with system in chemotherapy as part of a multidisciplinary approach because recurrent disease frequently develops after hepatectomy.

###### 

Summary of studies with ≥ 40 patients who underwent hepatectomy for liver metastasis from melanoma

  **Ref**.                                               **Year**   **Period**   **No. of patients**                     **Ocular/cutaneous**   **MST (mo) (ocular/cutaneous)**     **3-ysr (%)**                       **5-ysr (%)**                    **Factors associated with worse overall survival**
  ------------------------------------------------------ ---------- ------------ --------------------------------------- ---------------------- ----------------------------------- ----------------------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------
  Adam et al\[[@B10]\][1](#T7FN1){ref-type="table-fn"}   2006       1983-2004    148                                     104/44                 19/27                               NR                                  21 (ocular)/22 (cutaneous)       NR
  Pawlik et al\[[@B44]\]                                 2006       1988-2004    40                                      16/24                  28 \[29 (ocular)/24 (cutaneous)\]   62 (ocular)/48 (cutaneous) (2-yr)   11 (21 (ocular)/0 (cutaneous))   Cutaneous melanoma, no preoperative chemotherapy (in cutaneous melanoma) (univariable)
  Mariani et al\[[@B45]\]                                2009       1991-2007    255 (R2 = 157)                          255/0                  14 (27 mo after R0 resection)       NR                                  7                                Interval from primary tumor diagnosis ≤ 24 mo, R1 and R2, number of the metastases \> 4, miliary disease
  Mariani et al\[[@B46]\]                                2016       2000-2013    70 (inclding 13 concomitant with RFA)   70/0                   27 (hepatectomy), 28 (+RFA)         NR                                  NR                               NR

As a part of the report of on-colorectal non-neuroendocrine liver metastases. MST: Median survival time; ysr: Year survival rate; NR: Not reported.

LIVER METASTASES FROM SARCOMA
=============================

The six largest studies on the resection of liver metastases from sarcoma reported 50%-65% and 13%-46% overall 3- and 5-year survival rates, respectively, with median survival times of 24-72 mo (Table [8](#T8){ref-type="table"})\[[@B13],[@B26],[@B48]-[@B51]\]. Negative risk factors for overall survival in this cohort were a time of \< 24 mo from the diagnosis of primary tumor to the time of liver metastasis\[[@B26],[@B51]\], non-GIST\[[@B49]\], leiomyosarcoma\[[@B50]\], extrahepatic disease\[[@B51]\], and positive resection margins\[[@B51]\] (Table [8](#T8){ref-type="table"}). These studies included some GIST patients particularly in the early study periods because GIST had been considered as leiomyosarcoma before around 1993. Repeat hepatic resection was reported in four studies. Lang et al\[[@B48]\] reported 9 second and 2 third cases of hepatectomy for intrahepatic recurrent sarcoma. Less sensitivity to chemotherapy might prompt the surgeon to conduct a repeat hepatectomy with R0 resection, resulting in a favorable outcome\[[@B48]\].

###### 

Summary of studies with relatively large cohort of patients who underwent hepatectomy for liver metastasis from sarcoma

  **Ref**.                                                   **Year**   **Period**   **No. of patients**                                      **MST (mo)**                                   **3-ysr (%)**                        **5-ysr (%)**                        **Factors associated with worse overall survival**
  ---------------------------------------------------------- ---------- ------------ -------------------------------------------------------- ---------------------------------------------- ------------------------------------ ------------------------------------ ---------------------------------------------------------------------------------------
  Lang et al\[[@B48]\]                                       2000       1982-1996    26 (including 9 second, 2 third resection)               32 (R0 first resection), 21 (R1,2 resection)   NR                                   13                                   NR
  DeMatteo et al\[[@B26]\][1](#T8FN1){ref-type="table-fn"}   2001       1982-2000    56[1](#T8FN1){ref-type="table-fn"}                       39[1](#T8FN1){ref-type="table-fn"}             50[1](#T8FN1){ref-type="table-fn"}   30[1](#T8FN1){ref-type="table-fn"}   Time to liver metastasis from the primary tumor diagnosis ≤ 24 mo
  Pawlik et al\[[@B49]\]                                     2006       1996-2005    53 (35Hx, 18RF + Hx, and 13RF), (including 36 GISTs)     47[2](#T8FN2){ref-type="table-fn"}             65[2](#T8FN2){ref-type="table-fn"}   27[2](#T8FN2){ref-type="table-fn"}   Non-GIST
  Marudanayagam et al\[[@B50]\]                              2011       1997-2009    36[1](#T8FN1){ref-type="table-fn"} (including 5 GISTs)   24                                             48                                   32                                   Primaly leiomyosarcoma
  Groeschl et al\[[@B13]\][3](#T8FN3){ref-type="table-fn"}   2012       1990-2009    98                                                       72                                             60                                   32                                   NR
  Zhang et al\[[@B51]\]                                      2015       2000-2009    27                                                       NR                                             NR                                   46                                   Interval from primary tumor diagnosis ≤ 24 mo, extrahepatic disease, positive margins

Including some patients with GIST before 1993, GISTs were considered as leiomyosarcomas;

Including results of RF and patients with GIST;

As a part of the report of on-colorectal non-neuroendocrine liver metastases. GIST: Gastrointestinal stromal tumor; MST: Median survival time; ysr: Year survival rate; NR: Not reported; Hx: Hepatectomy; RF: Radiofrequency ablation.

LIVER METASTASES FROM GENITOURINARY TUMORS
==========================================

Genitourinary tumors mainly comprise renal cell carcinoma, gynecological carcinoma most commonly with ovarian cancer, and testicular cancer. In the present report, we have reviewed 6 studies pertaining to liver metastases from the renal cell carcinoma which reported overall 3- and 5-year survival rate of 54%-68% and 38%-62%, respectively, with median survival times of 33-142 mo (Table [9](#T9){ref-type="table"})\[[@B10],[@B16],[@B52]-[@B55]\]. The negative prognostic risk factors were the resection margin\[[@B52],[@B54]\], high-grade tumor\[[@B53]\], poor performance status\[[@B53]\], lymph node metastasis\[[@B53]\], synchronous metastasis\[[@B54]\], short disease-free interval\[[@B55]\], and extra hepatic disease\[[@B55]\] (Table [9](#T9){ref-type="table"}). Staehler et al\[[@B53]\] is the first to advocate a favorable prognosis for hepatectomy in patients who underwent resection of liver metastases from renal cell carcinoma over the prognosis of patients who refused to undergo hepatectomy for metastatic renal cell carcinoma, albeit the requirement for further systemic treatment.

###### 

Summary of studies with relatively large cohort of the patients who underwent hepatectomy for liver metastasis from genitourinary primary tumor

  **Disease**            **Ref**.                                                     **Year**   **Period**   **No. of patients**                                                  **MST (mo)**                                       **3-ysr (%)**   **5-ysr (%)**   **Factors associated with worse overall survival**
  ---------------------- ------------------------------------------------------------ ---------- ------------ -------------------------------------------------------------------- -------------------------------------------------- --------------- --------------- --------------------------------------------------------------------------------------------------------------------------
  Renal cell carcinoma   Adam et al\[[@B10]\][1](#T9FN1){ref-type="table-fn"}         2006       1983-2004    85                                                                   36                                                 NR              38              NR
                         Thelen et al\[[@B52]\]                                       2007       1988-2006    31                                                                   48                                                 54              39              Resection margin (R1,2)
                         Staehler et al\[[@B53]\]                                     2010       1995-2006    68                                                                   142                                                NR              62              High-grade primary renal cell carcinoma, performance status ≥ 1, lymph node status
                         Ruys et al\[[@B54]\]                                         2011       1990-2008    29                                                                   33                                                 47              43              Synchronous metastases, R1,2 resection margin (univariate)
                         Hatzaras et al\[[@B55]\]                                     2012       1994-2011    43                                                                   Not reached                                        62              NR              Disease-free interval ≤ 12 mo, exrahepatic disease (univariate)
                         Schiergens et al\[[@B16]\][1](#T9FN1){ref-type="table-fn"}   2016       2003-2013    28                                                                   50                                                 68              NR              NR
  Gyneclogic primary     Kamel et al\[[@B56]\]                                        2011       1990-2010    52                                                                   53                                                 57              41              NR
  Ovarian cancer         Merideth et al\[[@B57]\]                                     2003       1976-1999    26[2](#T9FN2){ref-type="table-fn"}                                   26                                                 NR              NR              Interval from the primary diagnosis \< 12 mo, residual disease \> 1 cm (univariate)
                         Adam et al\[[@B10]\][1](#T9FN1){ref-type="table-fn"}         2006       1983-2004    65                                                                   98                                                 NR              50              NR
                         Lim et al\[[@B58]\]                                          2009       2001-2008    14[2](#T9FN2){ref-type="table-fn"}                                   Not reached                                        NR              51              Hematogeneous liver metastasis \< hepatic parenchymal metastasis from peritoneal seeding[5](#T9FN5){ref-type="table-fn"}
                         Neumann et al\[[@B59]\]                                      2012       1991-2007    41                                                                   42(R0 resection)                                   NR              NR              R1,2 resection, pre-operative ascites, bilobular liver metastasis
                         Niu et al\[[@B60]\]                                          2012       2000-2011    60                                                                   39                                                 NR              30              R1,2 resection
                         Kolev et al\[[@B61]\]                                        2014       1988-2012    27[3](#T9FN3){ref-type="table-fn"}                                   56                                                 NR              NR              Interval from the primary surgery ≤ 24 mo, residual disease ≥ 1 cm
                         Bacalbasa et al\[[@B62]\]                                    2015       2002-2014    31[2](#T9FN2){ref-type="table-fn"}[4](#T9FN4){ref-type="table-fn"}   16 (metastasis from seeding), 13 (hematogeneous)   NR              NR              No significant risk factor
                         Schiergens et al\[[@B16]\][1](#T9FN1){ref-type="table-fn"}   2016       2003-2013    24                                                                   33                                                 43              NR              NR
  Testicular cancer      Hahn et al\[[@B63]\]                                         1999       1974-1996    57                                                                   NR                                                 97 (2-yr)       NR              NR
                         Adam et al\[[@B10]\][1](#T9FN1){ref-type="table-fn"}         2006       1983-2004    78                                                                   82                                                 NR              51              NR

As a part of the report of on-colorectal non-neuroendocrine liver metastases;

As a part of debulking surgery;

Hepatectomy as secondary cytoreduction;

Including 2^nd^ (*n* = 15), 3^rd^ (3) and 4^th^ (2) cytoreduction operations;

Only risk factors that included patients undergoing palliative treatment were reported. MST: Median survival time; ysr: Year survival rate; NR: Not reported.

The nine largest studies pertaining to gynecological primary cancers, particularly with ovarian cancer, reported 5-year overall survival rates of 30%-51% with median survival times of 26-98 mo (Table [9](#T9){ref-type="table"})\[[@B10],[@B16],[@B56]-[@B62]\]. Factors associated with worse survival were shorter interval from the diagnosis of primary disease to metastasis\[[@B56],[@B61]\], residual tumor measuring \> 1 cm\[[@B56],[@B61]\], hematogenous liver metastasis\[[@B57]\], positive resection margins\[[@B59],[@B60]\], pre-operative ascites\[[@B59]\], and bi-lobular hepatic metastasis\[[@B59]\] (Table [9](#T9){ref-type="table"}). Owing to the unique features of ovarian cancer, hepatectomy was regarded as a part of cytoreductive surgery and concomitant chemotherapy, which has been accepted as the standard treatment for advanced ovarian cancer. In contrast to other NCNNLMs, the resection of liver metastases from the peritoneal seeding showed better prognosis than resection of hematogenous liver metastases\[[@B57]\].

Chemotherapy is highly effective in the treatment of testicular carcinoma; however, one-third of the patients either did not achieve complete responces or experienced relapses\[[@B63]\]. The limited studies involving treatment with sensitive chemotherapy and subsequent hepatectomy for testicular carcinoma have sufficiently demonstrated a favorable prognosis in patients who underwent this treatment regimen\[[@B63]\].

CONCLUSION
==========

The clinical evidence accumulated with regards to NCNNLM has indicated the possibility of a chemotherapy-free period and a few studies have demonstrated a curing potential; however, almost all studies reviewed in the present report were conducted retrospectively in selected patients who underwent hepatic resection, which makes determining the absolute indications for hepatectomy in patients with NCNNLM challenging. Indications of hepatectomy for NCNNLM change according to the development of chemotherapy regimens. Strong and highly effective chemotherapy regimens might either expand the indications for hepatectomy or replace hepatectomy in this field. A multidisciplinary approach is required for the treatment of patients with diseases that are otherwise difficult to treat.
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